Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Step by step instructions to Involve Compact disc Rates for Magnanimous Giving - 2Inside the cockpit of RAF tanker during defensive mission against Iranian drones
- 3Watch This Glacier Race into the Sea
- 4Toddler diagnosed with cancer makes remarkable recovery after aggressive treatment
- 5Pedal Power: Divulging Well known Bike Brands for Each Cyclist
- Elvis Presley's Infamous Pantera Shooting
- Support Your Body: A Manual for Smart dieting and Sustenance
- Fundamental Home Machines for Improved Solace in Summer
- Doctors thought he had cancer. An offhand suggestion led to a rare diagnosis.
- Russia Establishing Long-Range Drone Bases In Belarus, Warns Ukraine
- ‘Ukrainian housewives’ and Skyranger delays – German defense poster child Rheinmetall is in hot water
- 'Crammed into a cell with vermin at New Year'
- Merz visit highlights new strategic, and strained, Germany-Israel bond
- Step by step instructions to Keep up with the Life span of Your Kona SUV's Battery Duration
